Betting On The CAR-T Race

Betting On The CAR-T Race


Clinical development of additional CAR-T indications and combination therapies is complicated by the personalized medicine nuance of this type of immuno-oncology. Let's take a moment to celebrate the FDA advisory committee's recommendation for approval of Novartis' biologic license to market CTL019.



from Biotech News